Reports PROCYSBI ® net product sales of $12.1 million in first quarter 2014 and launch of PROCYSBI ® in Germany Company to host conference call and webcast today at 4:30 p.m. EDT NOVATO, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today reported financial results for the first quarter ended March 31, 2014 and provided an update on recent corporate developments. Corporate Update and Operational Highlights
- Net product sales for PROCYSBI ® for the first quarter ended March 31, 2014 were $12.1 million, demonstrating a 20% quarter over quarter growth. PROCYSBI became commercially available in the U.S. in June 2013.
- As of March 31, 2014, 199 cumulative unique patients have received PROCYSBI, representing 20% quarter over quarter growth.
- The EU launch of PROCYSBI is underway in Germany, with initial product shipments in April at an average annualized price of €144,000.
- Cash and cash equivalents as of March 31, 2014 were $68.1 million.